Canopy, Growth

Canopy Growth Clears Major Hurdle in Acquisition Strategy

Published on 02/19/2026 at 23:30 | Redaktion boerse-global.de

MTL Cannabis shareholders voted 99.97% in favor of acquisition by Canopy Growth, a key step to create a leading medical cannabis firm pending final approvals.

Canopy Growth Clears Major Hurdle in Acquisition Strategy Illustration mit AI erstellt übermittelt durch boerse-global.de
Canopy Growth Clears Major Hurdle in Acquisition Strategy Illustration mit AI erstellt übermittelt durch boerse-global.de

Shareholders of MTL Cannabis have delivered a near-unanimous verdict, approving their company's acquisition by Canadian cannabis producer Canopy Growth. This decisive vote represents a critical step forward in Canopy Growth's plan to bolster its medical cannabis operations, though final regulatory approvals are still pending.

Overwhelming Shareholder Support Paves the Way

The shareholder meeting held this Tuesday yielded an exceptionally clear mandate. An overwhelming 99.97% of the votes cast were in favor of the transaction. Notably, voter turnout was remarkably high at approximately 89%. Even under stricter rules accounting for minority protection, the approval rate stood at an impressive 99.80%.

Under the terms of the deal, MTL Cannabis shareholders will receive 0.32 Canopy Growth shares plus a cash payment of CAD $0.144 for each share they own. Luc Mongeau, Chief Executive Officer of MTL Cannabis, characterized the result as a strong endorsement of the strategic vision to create Canada's leading medical cannabis company through this merger. The combined entity aims to leverage MTL's cultivation expertise with Canopy's distribution network.

Financial Rationale and Complementary Performance

The acquisition is strategically positioned to strengthen Canopy Growth's financial profile. MTL Cannabis recently reported annual revenue of CAD $84 million with an unadjusted gross margin of 51%. These figures complement Canopy's own recent performance, which included a 15% year-over-year revenue increase in its medical segment to CAD $23 million for the third fiscal quarter. Furthermore, Canopy succeeded in reducing its adjusted EBITDA loss to CAD $3 million.

Should investors sell immediately? Or is it worth buying Canopy Growth?

Path to Finalization and Closing Timeline

With shareholder consent secured, the process now moves to the legal phase. MTL Cannabis is scheduled to seek a final court order from the Supreme Court of British Columbia on Monday, February 23, 2026. Assuming the court approves the arrangement and all other customary closing conditions are satisfied, Canopy Growth anticipates completing the acquisition before the end of March 2026.

Ad

Canopy Growth Stock: New Analysis - 20 February

Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Canopy Growth analysis...

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | CA1380351009 | CANOPY | boerse | 68594250 |